^
Association details:
| Biomarker: | MET overexpression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Tepmetko (tepotinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tepotinib Inhibits the Epithelial-Mesenchymal Transition and Tumor Growth of Gastric Cancers by Increasing GSK3ß, E-Cadherin, and Mucin 5AC and 6 Levels
Published date:
08/21/2020
Excerpt:
To evaluate whether tepotinib induces cell death differentially depending on c-MET status, we used various GC cells with different c-MET expression statuses (MKN45 and SNU620 cells: high-c-MET; KATO III cells: low-c-MET; MKN28 and AGS cells: very low-c-MET) to assess early apoptotic, late apoptotic, and necrotic cell populations (Figure 3 and Figure 4a). Tepotinib significantly induced apoptosis in SNU620, MKN45, and KATO III cells, whereas apoptosis was rarely observed in MKN28 and AGS cells (Figure 3).
DOI:
10.3390/ijms21176027
